Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Core Viewpoint - Psyence Biomedical Ltd. has adjourned its annual and special meeting of shareholders to February 12, 2026, due to not achieving the required quorum [1][2] Company Overview - Psyence Biomedical Ltd. is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics, particularly nature-derived psilocybin and ibogaine [3] - The company is the first life sciences biotechnology firm focused on developing non-synthetic psychedelic medicine to be listed on Nasdaq, aiming to address unmet mental health needs [3] Meeting Details - The adjourned meeting will take place on February 12, 2026, at 9:00 a.m. New York Time/4:00 p.m. Cape Town time at Venture Workspace Riverlands, Cape Town, South Africa [1] - The record date for the meeting remains unchanged, set at the close of business on December 23, 2025 [2]